ALS News Today

FDA clears pivotal Phase 3 trial of new ALS oral therapy pridopidine

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...
TipRanks on MSN

Coya Therapeutics receives $4.2M milestone payment

Coya Therapeutics, Inc. ( ($COYA) ) has shared an announcement. On December 16, 2025, Coya Therapeutics, Inc. received a $4.2 million milestone ...
The Manila Times

PathMaker Neurosystems Receives FDA Breakthrough Device Designation For Use of the MyoRegulator® Neuromodulation Device in ALS For Slowing the Progression of Functional Symptoms

PathMaker Neurosystems Inc. ('PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s ...
Princeton University

The search for the next big breakthrough at Princeton

What will be the next blockbuster research to emerge from Princeton’s labs? No one can say for sure, but history tells us ...

Water pollution puts Floridians at risk of severe health problems

By Zachary T. Sampson, Shreya Vuttaluru and Bethany Barnes Times Staff Writers Dec. 17, 2025 When they arrived in Longboat ...